GlassScriptPhysician profile
Tiffany B Ward
NPI 1619186269
$3,739.63
in general payments reported to CMS, 2019-2025
28 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2021: $265 · 2022: $385 · 2023: $560 · 2024: $1,036 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,461.65 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Pfizer INC. | $421.88 | 2023-2025 | |
| Eisai INC. | $381.03 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $223.42 | 2019-2025 | |
| Amgen INC. | $203.48 | 2019-2025 | Uplizna, Aimovig |
| Genzyme Corporation | $140.29 | 2019-2025 | |
| Neurelis, INC. | $139.30 | 2024-2025 | Valtoco |
| Ucb, INC. | $89.44 | 2019-2025 | Nayzilam, Briviact |
| Lundbeck LLC | $73.72 | 2024-2025 | Vyepti |
| Lilly USA, LLC | $73.17 | 2019-2024 | Amyvid, Emgality |
| Supernus Pharmaceuticals, INC. | $66.65 | 2019 | |
| Celgene Corporation | $64.54 | 2024-2025 | Zeposia |
| Acadia Pharmaceuticals INC | $55.49 | 2019-2025 | Nuplazid |
| Argenx US, INC. | $51.89 | 2022-2024 | Vyvgart |
| Biogen, INC. | $35.99 | 2019-2024 | Vumerity, Tysabri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $27.36 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.38 | 2022 | |
| Allergan, INC. | $24.39 | 2022 | |
| Janssen Biotech, INC. | $23.16 | 2025 | |
| Emd Serono, INC. | $21.93 | 2024 | |
| Vanda Pharmaceuticals INC. | $20.80 | 2024 | Ponvory |
| Neurocrine Biosciences, INC. | $20.41 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $19.02 | 2019 | |
| Genentech USA, INC. | $17.86 | 2019 | |
| Bausch Health US, LLC | $17.38 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.78 | 2022 | |
| Horizon Therapeutics Plc | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.